NLSP Research and Charts

NLSP - NLS Pharmaceutics Ltd Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 2.89	Change ⇑ +0.25 (+9.47%)	Volume 71,936
	Open 3.11	High 3.25	Low 2.65

8EMA (Daily) 2.71	40EMA (Daily) 2.67	50EMA (Daily) 2.69	STO (Daily) 51.324	MACD Hist (Daily) 0.028
8EMA (Weekly) 2.689	40EMA (Weekly) 2.55	50EMA (Weekly) 2.46	STO (Weekly) 26.067	MACD Hist (Weekly) -0.041


Company Profile
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. The company focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. The Company's lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD (Attention Deficit Hyperactivity Disorder).

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.